πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9162980

Anti-depression compounds

The Board of Regents of the University of Texas System Β· Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9150648

Anti-ASIC1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9139634

Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activiti

The Regents of the University of California Β· Granted Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9132192

Anti-EGFR antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9127057

Anti-IL-23 heterodimer specific antibodies

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD Β· Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9127053

Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and m

CytomX Therapeutics, Inc. Β· Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9101670

Conjugates of an anti-TNF-Ξ± antibody

Nektar Therapeutics Β· Granted Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9102744

Conjugated anti-CD38 antibodies

Takeda Pharmaceutical Company Limited Β· Granted Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9095539

Anti-adhesin based passive immunoprophylactic

United States of America as represented by the Secretary of the Air Force Β· Granted Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9095608

Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD

The Regents of the University of Colorado Β· Granted Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9095558

Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applicati

The Board of Regents of the University of Texas System Β· Granted Tue Aug 04 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9084762

T-cell immunogens derived from anti-viral proteins and methods of using same

The Regents of the University of California Β· Granted Tue Jul 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9072767

Anti-regurgitation and/or anti-gastrooesophageal reflux composition, preparation and uses

UNITED PHARMACEUTICALS Β· Granted Tue Jul 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9073884

Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using

The Regents of the University of California Β· Granted Tue Jul 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9044457

Anti-DR4 agonist antibodies

The United States of America as Represented by the Secretary of the Department of Health and Human Services Β· Granted Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9017670

Anti-Tie2 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9018356

Anti-ANGPTL3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9012647

Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treat

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Apr 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9006399

Anti-OX40 antibodies and methods of using the same

The Board of Regents of the University of Texas System Β· Granted Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8987305

2,4,5-trisubstituted imidazoles and their use as anti-microbial agents

APTOSE BIOSCIENCES INC. Β· Granted Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8980268

Methods for treating cancer by administering an anti-Ang-2 antibody

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8969372

Aryl imidazoles and their use as anti-cancer agents

Aptose Boisciences Inc. Β· Granted Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8945559

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8940298

High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and d

The Regents of the University of California Β· Granted Tue Jan 27 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted